The research company Curasight reports, as planned, no revenue for the second quarter. The operating loss decreased.Operating result was DKK 11.5 million (19.0). Profit before tax was DKK 12.8 million (20.6). Net result was DKK 11.4 million (19.2). Cash flow from operating activities amounted to DKK 15.8 million (22.5). Cash and cash equivalents amounted to DKK 41.0 million (29.4).Curasight now expects top-line data from the phase 1 study of uTREAT in glioblastoma during the first half of 2027. Data from the phase 2 study of uTRACE in prostate cancer, which is being conducted together with Curium, is also expected during the same period, CEO Ulrich Krasilnikoff says.The updated timelines are primarily due to uncertainty surrounding the final patient recruitment. The company's focus going forward is to advance the uTREAT programme, subject to regulatory approval of the proposed protocol amendment, and complete the phase 2 study in prostate cancer. Curasight, DKK millionQ2-2026Q2-2025ChangeNet sales00Operating result-11.5-19.0Profit before tax-12.8-20.6Net result-11.4-19.2Cash flow from operating activities-15.8-22.5Cash and cash equivalents41.029.439.5%